Moderna announces promising interim data for its avian influenza vaccine mRNA-1018 but faces a setback as the U.S. government terminates the funding contract. This contract, initially valued at $176 million and expanded to $590 million, was crucial for advancing the vaccine trials against avian flu. The company highlights the advantage of the mRNA technology's speed to respond to emerging pathogens compared to traditional vaccines. Despite showing strong immune responses in early phase trials, the future of mRNA-1018 now hangs in balance due to the funding loss amid ongoing avian flu outbreaks.
The avian influenza vaccine candidate mRNA-1018 showed promising interim results, yet the U.S. government has canceled the contract that would fund its late-stage trials.
Moderna's mRNA-1018 vaccine exhibited rapid and durable immune responses in trials, highlighting the effectiveness of mRNA technology against public health threats like avian influenza.
Collection
[
|
...
]